Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 6 · 85.7%Moderate 1 · 14.3%High 0 · 0%

ICS + LAMA add‐on vs ICS dose increase

Mean exacerbations requiring a course of oral corticosteroids · adults with asthma

ICS + LAMA add‐on showed no clear difference in exacerbations requiring a course of OCSa 14 weeks compared with ICS dose increase (low certainty).

1 finding from 1 review

Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults… 2015 · Cochrane Headline outcomes only
OR 0.57 [0.22, 1.43]
1 study · 174 participants
Low

ICS + LAMA add‐on vs ICS dose increase

AQLQ score (Scale 1 to 7, where 1 = severely impaired and 7 = no impairment) · adults with asthma

1 finding from 1 review

Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults… 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1 participants
Low

ICS + LAMA add‐on vs ICS dose increase

SAEs · adults with asthma

ICS + LAMA add‐on showed no clear difference in SAEs (all cause) compared with ICS dose increase (low certainty).

1 finding from 1 review

Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults… 2015 · Cochrane Headline outcomes only
OR 1 [0.2, 5.09]
1 study · 174 participants
Low

ICS + LAMA add‐on vs ICS dose increase

Exacerbations needing hospitalisation · adults with asthma

ICS + LAMA add‐on showed no clear difference in exacerbations requiring hospitalisation 14 weeks compared with ICS dose increase (low certainty).

1 finding from 1 review

Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults… 2015 · Cochrane Headline outcomes only
OR 1 [0.06, 16.24]
1 study · 174 participants
Low

ICS + LAMA add‐on vs ICS dose increase

Exacerbations leading to ED visits · adults with asthma

ICS + LAMA add‐on showed no clear difference in exacerbations requiring ED visit 14 weeks compared with ICS dose increase (low certainty).

1 finding from 1 review

Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults… 2015 · Cochrane Headline outcomes only
OR 0.49 [0.09, 2.77]
1 study · 174 participants
Low

ICS + LAMA add‐on vs ICS dose increase

FEV1 · adults with asthma

1 finding from 1 review

Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults… 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1 participants
Moderate

ICS + LAMA add‐on vs ICS dose increase

ACQ score Scale = 0 to 6 (0 = no impairment; 6 = maximum impairment) · adults with asthma

1 finding from 1 review

Long‐acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus higher dose ICS for adults… 2015 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1 participants
Low